OR WAIT null SECS
February 18, 2016.
The Asia-Pacific (APAC) breast cancer market is set to grow from $1.9 billion in 2014 to $3.4 billion by 2021, according to GBI Research.
Aging populations, changing lifestyle habits, improved survival rates, and a number of new approvals for drugs that are expected to supplement current market leaders will fuel market growth across India, China, Australia, and Japan, the company reports.
GBI analyst Deekshita Allavarapu said that popular drugs, such as Afinitor and Herceptin, will be used in conjunction with several promising breast cancer pipeline treatments. "These include abemaciclib, buparlisib, LEE 011, olaparib, and Neuvax, all of which are forecast to be approved by 2021 and have shown significant clinical benefit in trials." She added, "In addition, the strong efficacy profile of targeted therapies has resulted in favourable reimbursement and increased uptake in Japan and Australia. This is despite the drugs' premium pricing, which reflects the cost associated with their development and the significant therapeutic benefit offered."
However, the analyst notes that in India and China, even after premium targeted treatments become available, only patients in the richer territories will be given these drugs, as patients in the poorer districts will not be able to afford them due to a lack of social insurance and inadequately publicly subsidized services.
See here for more on the GBI report: